These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 30126537)

  • 1. Comparison between buprenorphine provider availability and opioid deaths among US counties.
    Jones CW; Christman Z; Smith CM; Safferman MR; Salzman M; Baston K; Haroz R
    J Subst Abuse Treat; 2018 Oct; 93():19-25. PubMed ID: 30126537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
    Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
    JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparities Between US Opioid Overdose Deaths and Treatment Capacity: A Geospatial and Descriptive Analysis.
    Langabeer JR; Gourishankar A; Chambers KA; Giri S; Madu R; Champagne-Langabeer T
    J Addict Med; 2019; 13(6):476-482. PubMed ID: 30844879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of Buprenorphine Treatment in the 10 States With the Highest Drug Overdose Death Rates in the United States.
    Flavin L; Malowney M; Patel NA; Alpert MD; Cheng E; Noy G; Samuelson S; Sreshta N; Boyd JW
    J Psychiatr Pract; 2020 Jan; 26(1):17-22. PubMed ID: 31913966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
    Kazerouni NJ; Irwin AN; Levander XA; Geddes J; Johnston K; Gostanian CJ; Mayfield BS; Montgomery BT; Graalum DC; Hartung DM
    Drug Alcohol Depend; 2021 Jul; 224():108729. PubMed ID: 33932744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
    Kelty E; Hulse G
    Int J Drug Policy; 2017 Aug; 46():54-60. PubMed ID: 28609749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.
    Ghertner R
    Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
    Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
    Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
    Morgan JR; Schackman BR; Weinstein ZM; Walley AY; Linas BP
    Drug Alcohol Depend; 2019 Jul; 200():34-39. PubMed ID: 31082666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Medicaid Expansion With Opioid Overdose Mortality in the United States.
    Kravitz-Wirtz N; Davis CS; Ponicki WR; Rivera-Aguirre A; Marshall BDL; Martins SS; Cerdá M
    JAMA Netw Open; 2020 Jan; 3(1):e1919066. PubMed ID: 31922561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
    Krawczyk N; Jent V; Hadland SE; Cerdá M
    J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Two Databases to Identify Access to Buprenorphine Treatment for Opioid Use Disorder.
    Anyanwu P; Varisco TJ; Wanat MA; Bapat S; Claborn K; Thornton JD
    J Pain Palliat Care Pharmacother; 2022 Jun; 36(2):103-111. PubMed ID: 35648731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis.
    Knudsen HK
    J Stud Alcohol Drugs; 2015 Jul; 76(4):644-54. PubMed ID: 26098042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying counties at risk of high overdose mortality burden during the emerging fentanyl epidemic in the USA: a predictive statistical modelling study.
    Marks C; Abramovitz D; Donnelly CA; Carrasco-Escobar G; Carrasco-Hernández R; Ciccarone D; González-Izquierdo A; Martin NK; Strathdee SA; Smith DM; Bórquez A
    Lancet Public Health; 2021 Oct; 6(10):e720-e728. PubMed ID: 34118194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid Use Disorder and Pregnancy.
    O'Donnell FT; Jackson DL
    Mo Med; 2017; 114(3):181-186. PubMed ID: 30228577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018.
    Conway KP; Khoury D; Hilscher R; Aldridge AP; Parker SJ; Zarkin GA
    Addict Sci Clin Pract; 2022 Jan; 17(1):5. PubMed ID: 35101112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality.
    Lei F; Lofwall MR; McAninch J; Adatorwovor R; Slade E; Freeman PR; Moga DC; Dasgupta N; Walsh SL; Vickers-Smith R; Slavova S
    J Addict Med; 2024 May-Jun 01; 18(3):319-326. PubMed ID: 38598300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities.
    Rizk JG; Saini J; Kim K; Pathan U; Qato DM
    PLoS One; 2024; 19(4):e0301863. PubMed ID: 38578818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.